Comparative efficacy of tirzepatide, teneligliptin, and empagliflozin in Hba1c reduction in patients with type 2 diabetes: a systematic review and meta-analysis
Int. j. med. surg. sci. (Print); 10 (3), 2023
This study’s objective was to evaluate the effectiveness of three different families of drugs (Empagliflozin [an SGLT-2 inhibitor], Tirzepatide [a GLP-1 receptor co-agonist], and Teneligliptin [DPP-4 inhibitor] used in the treatment of type 2 diabetes in lowering HbA1...
Diabetes Mellitus Tipo 2/diagnóstico, Diabetes Mellitus Tipo 2/terapia, Diabetes Mellitus Tipo 2/sangre, Diabetes Mellitus Tipo 2/tratamiento farmacológico, Hemoglobina Glucada/análisis, Hipoglucemiantes/administración & dosificación, Polipéptido Inhibidor Gástrico/uso terapéutico, Pirazoles/uso terapéutico, Compuestos de Bencidrilo